HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RIFM, European Scientists Work To Iron Out Differences On QRA Methodology

This article was originally published in The Rose Sheet

Executive Summary

The Research Institute for Fragrance Materials is in talks with industry representatives and European scientific authorities regarding its quantitative risk assessment (QRA) approach to fragrance sensitization, which has been received with varying degrees of enthusiasm

You may also be interested in...



IFRA’s New Prez On Fragrance Transparency, The Science/Society ‘Interface’

Four months into her presidency, the International Fragrance Association’s new head discusses key issues and priorities, including ingredient disclosure in a sector that jealously guards its trade secrets.

European Scientific Committee Not Budging On Recommended MI Restrictions

The Scientific Committee on Consumer Safety is not swayed by Cosmetic Europe's updated data submission suggesting that methylisothiazolinone can be safely used to preserve cosmetic products in concentrations as high as 100 ppm, taking issue with industry's Quantitative Risk Assessment model for dermal sensitization and tests cited in the trade group's calculations. The committee stands by its position that MI is unsafe for use in leave-on cosmetics and should be restricted to 15 ppm in rinse-off products.

In Brief

RIFM-Led Study Shows QRA Is Effective

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015754

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel